Drug Shortage Report for BREVIBLOC PREMIXED INJECTION

Last updated on 2025-03-13 History
Report ID 241095
Drug Identification Number 02309238
Brand name BREVIBLOC PREMIXED INJECTION
Common or Proper name BREVIBLOC Premix, Esmolol Hydrochloride Injection 2500 mg / 250 mL (10mg/mL)
Company Name BAXTER CORPORATION
Market Status MARKETED
Active Ingredient(s) ESMOLOL HYDROCHLORIDE
Strength(s) 10MG
Dosage form(s) SOLUTION
Route of administration INTRAVENOUS INTRAVENOUS
Packaging size 250mL (CA2J1415)
ATC code C07AB
ATC description BETA BLOCKING AGENTS
Reason for shortage Disruption of the manufacture of the drug.
Anticipated start date 2024-12-15
Actual start date 2024-12-15
Estimated end date 2025-03-14
Actual end date 2025-03-11
Shortage status Resolved
Updated date 2025-03-13
Company comments Product is on 75% allocation. Shortage is due to damage at North Cove manufacturing site. We currently have 57 DOS and are working on a plan to ensure future product can be manufactured
Health Canada comments
Tier 3 Status No
Contact Address 7125 MISSISSAUGA ROAD
MISSISSAUGA, ONTARIO
CANADA L5N 0C2
Company contact information

Version History

Click on "Compare" below to view the full report history and compare to other versions.

Version Number Date Updated Language
v18 2025-03-13 French Compare
v17 2025-03-13 English Compare
v16 2025-03-07 French Compare
v15 2025-03-07 English Compare
v14 2025-03-03 French Compare
v13 2025-03-03 English Compare
v12 2025-02-28 French Compare
v11 2025-02-28 English Compare
v10 2025-01-09 French Compare
v9 2025-01-09 English Compare
v8 2025-01-08 French Compare
v7 2025-01-08 English Compare
v6 2024-12-16 English Compare
v5 2024-10-24 French Compare
v4 2024-10-24 French Compare
v3 2024-10-24 French Compare
v2 2024-10-24 English Compare
v1 2024-10-24 English Compare

Showing 1 to 18 of 18